Search Results

You are looking at 91 - 100 of 488 items for :

  • Refine by Access: Content accessible to Me x
Clear All
Full access

examinations, MRI evaluations, and serum biomarker assessments. All patients will be treated until radiographic or clinical evidence is seen of disease progression or unacceptable toxicity. Patients may withdraw from the study at any time. Primary Objective

Full access

Stephen B. Edge

address in controlled clinical trials. Technological Advances and Controversies A major change in breast surgery practice has been the use of MRI. Compared with other breast imaging, breast MRI may provide better information on the extent of a

Full access

Benjamin L. Franc, Timothy P. Copeland, Robert Thombley, Miran Park, Ben Marafino, Mitzi L. Dean, W. John Boscardin, Hope S. Rugo, David Seidenwurm, Bhupinder Sharma, Stephen R. Johnston, and R. Adams Dudley

breast cancer diagnosed by age 50 years, receive dedicated breast MRI annually. 2 ASCO and NCCN have issued guidelines stating that, after initial treatment, surveillance for recurrence in patients with stage I–III breast cancer should include periodic

Full access

Bethany L. Niell

with a breast biopsy in 2010 through 2012. Claims for high-cost imaging studies, such as CT, brain or body MRI, PET, and bone scans, in the 18-month postoperative period were included if the imaging was performed for a breast cancer indication. The

Full access

Presenter: Julio M. Pow-Sang

MRI, prostate-specific membrane antigen (PSMA) PET/CT, genomic markers, and genetic testing. Dr. Pow-Sang also shared various management options for nonmetastatic prostate cancer, including active surveillance/observation, radiation therapy (RT), and

Full access

Kamran Aghayev, Frank Vrionis, and Marc C. Chamberlain

General Considerations Imaging MRI (with and without contrast) plays an essential role in the diagnosis of primary spinal cord tumors. Currently, no other imaging modality can be used alone to establish a diagnosis. Plain radiographs may show

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar, and Dorothy A. Shead

, determination of tumor estrogen receptor (ER) status, and MRI as indicated. For pathology reporting, the NCCN panel endorses the College of American Pathologists' protocol for both invasive and noninvasive carcinomas of the breast. 1 The NCCN Guidelines Panel

Full access

Mark D. Tyson and Sam S. Chang

annually up to 5 years. 2 If the patient underwent a partial nephrectomy, a baseline abdominal CT, MRI, or ultrasound is recommended within 3 to 12 months of surgery, then annually for 3 years if the baseline scan is negative. Recognizing that the risk of

Full access

Anne M. Covey

≥10 mm on ultrasound and capsular retraction or vascular invasion, further workup with CT or MRI would be required ( Figure 1 ). In the United States, Dr. Covey noted that CT and MRI seem to be used more often than ultrasound for detecting HCC. In

Full access

Dong-Xu Qiu, Jian Li, Jin-Wei Zhang, Min-Feng Chen, Xiao-Mei Gao, Yong-Xiang Tang, Ye Zhang, Xiao-Ping Yi, Hong-ling Yin, Yu Gan, Gui-Lin Wang, Xiong-Bing Zu, Shuo Hu, and Yi Cai

INTRODUCTION AND OBJECTIVE : Growing evidence proved the efficacy of multiparametric MRI (mpMRI) and prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)-guided targeted biopsy (TB) in prostate